ArticleMolecules (Basel, Switzerland)2022
Discovery of Leptulipin, a New Anticancer Protein from theIranian Scorpion,
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development.Archiv der Pharmazie · 2026Review
- Toxin-Derived Peptides as Potentials Weapons Against Cancer.Pharmaceutics · 2026Review
- The recombinant protein of scorpion venom phospholipase A2 exhibits potential anti-leishmanial activity.Scientific reports · 2025Article
- Properties and Pharmacology of Scorpion Toxins and Their Biotechnological Potential in Agriculture and Medicine.Toxins · 2025Review
- Recombinant α-Toxin BmK-M9 Inhibits Breast Cancer Progression by Regulating β-Catenin In Vivo.Cell biochemistry and biophysics · 2025Article
- Invertebrate venoms: A treasure trove of bioactive compounds with anticancer potential.Archives of toxicology · 2025Review
- Structural insights and predictive modelling of a novel anti-HER2 scFv and Leptulipin: a newly designed immunotoxin protein for HER2 positive cancers.Toxicology research · 2025Article
- Systematic Review of the Antitumor Activities and Mechanisms of Scorpion Venom on Human Breast Cancer Cells Lines (In Vitro Study).Journal of clinical medicine · 2025Review
- Biochemical characterization and activity profiling of recombinant phospholipase A2 from Hemiscorpius lepturus expressed in E. coli with in vivo antibody response.Scientific reports · 2025Article
- Ion-Channel-Targeting Scorpion Recombinant Toxin as Novel Therapeutic Agent for Breast Cancer.Toxins · 2025Article
- Article
- Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer.Toxicology research · 2024Article
- Scorpion Venom as a Source of Antimicrobial Peptides: Overview of Biomolecule Separation, Analysis and Characterization Methods.Antibiotics (Basel, Switzerland) · 2023Review
- Molecular Characterization and In Silico Analyses of Maurolipin Structure as a Secretory PhospholipaseJournal of tropical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the leading causes of mortality in the world. Unfortunately, the present anticancer chemotherapeutics display high cytotoxicity. Accordingly, the discovery of new anticancer agents with lower side effects is highly necessitated. This study aimed to discover an anticancer compound from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.